Effect of teriparatide compared with risedronate on back pain and incident vertebral fractures in postmenopausal women with osteoporotic vertebral fractures
Peyman Hadji(Philipps University of Marburg), John L. Stock(Eli Lilly (United States)), José Zanchetta(Universidad del Salvador), M.L. Lakshmanan(Eli Lilly (United States)), Kenneth G. Saag(University of Alabama at Birmingham), Chris Recknor(Bone Health and Osteoporosis Foundation), Daniel N. Masica(Eli Lilly (United States)), Jahangir Alam(Eli Lilly (United States)), John H. Krege(Eli Lilly (United States)), Bruce Mitlak(Radius Health (United States)), Fergus E. McKiernan(Marshfield Clinic), Russel Burge(Eli Lilly (United States)), Luis Augusto Tavares Russo, S. Silverman
Cited by 4
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis & Rheumatology|2015|2.8k